| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on September 14, 2005
Accepted on March 3, 2006
Lipids, Lipoproteins, and Cardiovascular Risk Factors |
1 Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany
2 Department of Epidemiology, German Centre for Research on Ageing, Heidelberg, Germany
* To whom correspondence should be addressed. E-mail: maximilian.eynatten{at}med.uni-heidelberg.de.
Background: Adiponectin, an adipocyte-derived hormone, appears to be a modulator of lipid metabolism and systemic inflammation and is present in particularly low concentrations in patients with coronary heart disease (CHD). However, the clinical importance of adiponectin in individuals at markedly high risk for future cardiovascular morbidity and mortality has not been fully elucidated. We examined the associations between serum adiponectin and several biomarkers related to cardiovascular disease and heart failure in a large high-risk population comprising patients with prevalent CHD.
Methods: We measured fasting adiponectin, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and markers of lipoprotein metabolism in 1174 patients with angiographically documented CHD.
Results: After adjustment for age and sex, adiponectin was associated with HDL-cholesterol (HDL-C; r = 0.25; P <0.0001), NT-proBNP (r = 0.17; P <0.0001), and plasma triglyceride (r = -0.21; P <0.0001) concentrations. There was, however, no statistically significant association between adiponectin and markers of systemic inflammation. In partial correlation analyses further adjusted for body mass index, alcohol intake, smoking status, presence of diabetes and/or hypertension, lipid-lowering drug therapy, and fasting plasma glucose, adiponectin remained significantly associated with HDL-C (r = 0.21; P <0.0001), NT-proBNP (r = 0.15; P <0.0001), and plasma triglycerides (r = -0.16; P <0.0001).
Conclusions: Serum adiponectin is associated with the presence of atherogenic dyslipidemia and with NT-proBNP concentration but not with markers of systemic inflammation in patients with manifest CHD. Thus, atherogenic dyslipidemia may link adiponectin with the progression of atherosclerosis. Moreover, serum adiponectin may be related to BNP in patients with CHD.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  C. Chung, A. Long, J. Solus, Y. Rho, A Oeser, P Raggi, and C. Stein Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis Lupus, August 1, 2009; 18(9): 799 - 806. [Abstract] [PDF]
|
|
|
|
 |
|
 M. von Eynatten, H. Brenner, and D. Rothenbacher Adiponectin and prognostic outcome in patients with coronary artery disease: reply Eur. Heart J., October 2, 2008; 29(20): 2579 - 2580. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cabre, I. Lazaro, J. Girona, J. M. Manzanares, F. Marimon, N. Plana, M. Heras, and L. Masana Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes J. Lipid Res., August 1, 2008; 49(8): 1746 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease Eur. Heart J., May 2, 2008; 29(10): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Polak, Z Kovacova, C Holst, C Verdich, A Astrup, E Blaak, K Patel, J M Oppert, D Langin, J A Martinez, et al. Total adiponectin and adiponectin multimeric complexes in relation to weight loss-induced improvements in insulin sensitivity in obese women: the NUGENOB study. Eur. J. Endocrinol., April 1, 2008; 158(4): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanaka, T. Tsutamoto, H. Sakai, K. Nishiyama, M. Fujii, T. Yamamoto, and M. Horie Effect of atrial natriuretic peptide on adiponectin in patients with heart failure Eur J Heart Fail, April 1, 2008; 10(4): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study Eur. Heart J., March 1, 2008; 29(5): 649 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, T. Tanaka, H. Sakai, C. Ishikawa, M. Fujii, T. Yamamoto, and M. Horie Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure Eur. Heart J., July 2, 2007; 28(14): 1723 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pischon and E. B. Rimm Adiponectin: a promising marker for cardiovascular disease. Clin. Chem., May 1, 2006; 52(5): 797 - 799. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
